SCHEMBL3754934

SCHEMBL3754934

N#C[CH]Cc1ccc(F)cc1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.39
KEAP1 Q14145 1/20 0.37
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
PARP1 P09874 5/20 0.36
PARP2 Q9UGN5 2/20 0.34
AURKA O14965 1/20 0.34
RPS6KB1 P23443 1/20 0.34
AURKB Q96GD4 1/20 0.34
MPO P05164 1/20 0.33
SLC6A4 P31645 1/20 0.33
MAPK10 P53779 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ICMT O60725 1/20 0.33
PARP14 Q460N5 1/20 0.33
PARP10 Q53GL7 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
KCNH2 Q12809 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5107612 0.83 LCK (0.37) PARP1ALDH1A1
SCHEMBL2925555 0.82 CASP1 (0.39) MAPK8PARP1PARP2PARP10KCNH2
SCHEMBL6802462 0.82 ALDH1A1 (0.46) ALDH1A1KDM4EGAA
SCHEMBL2927261 0.81 CES2 (0.43) CES2ALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL6803102 0.78 IKBKB (0.51)
SCHEMBL2921307 0.78 KDM4E (0.41) KEAP1ALDH1A1LMNATSHRKDM4E
SCHEMBL12023001 0.77 MAPK8 (0.46) MAPK8KEAP1CES2CES1PARP1
SCHEMBL6795801 0.76 PTGS2 (0.41) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL3769465 0.76 AURKA (0.35) MAPK8CES2CES1PARP1AURKA
SCHEMBL6755715 0.75 MAPK8 (0.44) MAPK8KEAP1CES2CES1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225196-B1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES MERCK CANADA INC (CA) 2015-01-28 EP disclosed
US-8642799-B2 Cysteine protease inhibitors for the treatment of parasitic diseases MERCK CANADA INC. (CA) 2014-02-04 US disclosed
US-20130244962-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES MERCK FROSST CANADA LTD. (CA) 2013-09-19 US disclosed
US-20100305056-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE MERCK FROSST CANADA LTD. (CA) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305056-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE CTSL, SERPINB1, CTSZ MAPK8 3453/4885KEAP1 250/4885CES2 1200/4885
US-20130244962-A1 CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES CTSL, SERPINB1, CTSZ MAPK8 3258/4885KEAP1 391/4885CES2 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.